Christopher C Rowe

Summary

Affiliation: Austin Health
Country: Australia

Publications

  1. ncbi request reprint Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease
    Kerryn E Pike
    School of Psychology, Psychiatry and Psychological Medicine, Monash University, Melbourne, Australia
    Brain 130:2837-44. 2007
  2. ncbi request reprint The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias
    Victor L Villemagne
    Department of Nuclear Medicine, Centre for PET, Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia
    Mol Neurobiol 38:1-15. 2008
  3. ncbi request reprint Imaging beta-amyloid burden in aging and dementia
    C C Rowe
    Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    Neurology 68:1718-25. 2007
  4. ncbi request reprint Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism
    Christopher C Rowe
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    Lancet Neurol 7:129-35. 2008
  5. doi request reprint Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
    Christopher C Rowe
    Austin Health, Department of Nuclear Medicine and Centre for PET, Heidelberg, Victoria, Australia
    Neurobiol Aging 31:1275-83. 2010
  6. pmc In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106
    Akihiro Takano
    Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm SE 171 77, Sweden
    EJNMMI Res 3:30. 2013
  7. doi request reprint Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia
    Christopher C Rowe
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    J Nucl Med 54:880-6. 2013
  8. doi request reprint Amyloid imaging with PET in early Alzheimer disease diagnosis
    Christopher C Rowe
    Department of Nuclear Medicine, Centre for PET, University of Melbourne, Austin Health, Heidelberg, Victoria 3084, Australia
    Med Clin North Am 97:377-98. 2013
  9. doi request reprint Brain amyloid imaging
    Christopher C Rowe
    Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia
    J Nucl Med Technol 41:11-8. 2013
  10. doi request reprint Brain amyloid imaging
    Christopher C Rowe
    Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia
    J Nucl Med 52:1733-40. 2011

Detail Information

Publications69

  1. ncbi request reprint Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease
    Kerryn E Pike
    School of Psychology, Psychiatry and Psychological Medicine, Monash University, Melbourne, Australia
    Brain 130:2837-44. 2007
    ..The data also suggests that early intervention trials for AD targeted to non-demented individuals with cerebral Abeta deposition are warranted...
  2. ncbi request reprint The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias
    Victor L Villemagne
    Department of Nuclear Medicine, Centre for PET, Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia
    Mol Neurobiol 38:1-15. 2008
    ..Further longitudinal observations are required to confirm this hypothesis and to better elucidate the role of Abeta deposition in the course of Alzheimer's disease...
  3. ncbi request reprint Imaging beta-amyloid burden in aging and dementia
    C C Rowe
    Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    Neurology 68:1718-25. 2007
    ..To compare brain beta-amyloid (Abeta) burden measured with [(11)C]Pittsburgh Compound B (PIB) PET in normal aging, Alzheimer disease (AD), and other dementias...
  4. ncbi request reprint Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism
    Christopher C Rowe
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    Lancet Neurol 7:129-35. 2008
    ..18)F-BAY94-9172 is an Abeta ligand that, due to the half-life of (18)F, is suitable for clinical use. We thus studied the effectiveness of this ligand in identifying patients with AD...
  5. doi request reprint Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
    Christopher C Rowe
    Austin Health, Department of Nuclear Medicine and Centre for PET, Heidelberg, Victoria, Australia
    Neurobiol Aging 31:1275-83. 2010
    ....
  6. pmc In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106
    Akihiro Takano
    Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm SE 171 77, Sweden
    EJNMMI Res 3:30. 2013
    ..18F]FEDAA1106 is a recently developed PET radioligand for the in vivo quantification of TSPO. In the present study, we aimed at investigating the diagnostic usefulness of [18F]FEDAA1106 in patients with MS...
  7. doi request reprint Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia
    Christopher C Rowe
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    J Nucl Med 54:880-6. 2013
    ..We compared the cortical and white matter binding of a new (18)F-labeled Aβ tracer, (18)F-AZD4694 (recently renamed NAV4694), with (11)C-PiB in the same subjects...
  8. doi request reprint Amyloid imaging with PET in early Alzheimer disease diagnosis
    Christopher C Rowe
    Department of Nuclear Medicine, Centre for PET, University of Melbourne, Austin Health, Heidelberg, Victoria 3084, Australia
    Med Clin North Am 97:377-98. 2013
    ..Longitudinal observations are required to elucidate the role of Aβ deposition in the course of Alzheimer disease and provide information needed to fully use the prognostic power of this investigation...
  9. doi request reprint Brain amyloid imaging
    Christopher C Rowe
    Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia
    J Nucl Med Technol 41:11-8. 2013
    ..This article will provide nuclear medicine physicians with the background knowledge required for understanding this emerging investigation, including its appropriate use, and prepare them for practical training in scan interpretation...
  10. doi request reprint Brain amyloid imaging
    Christopher C Rowe
    Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia
    J Nucl Med 52:1733-40. 2011
    ..This article will provide nuclear medicine physicians with the background knowledge required for understanding this emerging investigation, including its appropriate use, and prepare them for practical training in scan interpretation...
  11. ncbi request reprint Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing
    Christopher C Rowe
    Austin Health, Department of Nuclear Medicine and Centre for Positron Emission Tomography, Heidelberg, Victoria, Australia
    Ann Neurol 74:905-13. 2013
    ..We aimed to determine the prognostic value of β-amyloid imaging, alone and in combination with memory performance, hippocampal atrophy, and apolipoprotein E ε4 status in nondemented, older individuals...
  12. ncbi request reprint Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease
    Yen Ying Lim
    1 The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
    Brain 137:221-31. 2014
    ..Further, these results suggest that grouping amyloid data into at least two categories of abnormality may be useful in determining the disease risk level in non-demented individuals. ..
  13. pmc Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia
    Ann Neurol 69:181-92. 2011
    ..Assess Aβ deposition longitudinally and explore its relationship with cognition and disease progression...
  14. ncbi request reprint Relationship between atrophy and beta-amyloid deposition in Alzheimer disease
    Gael Chetelat
    Department of Nuclear Medicine and Center for PET, Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia
    Ann Neurol 67:317-24. 2010
    ..The present study aims to assess this relationship...
  15. ncbi request reprint Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging
    Victor L Villemagne
    Mental Health Research Institute, University of Melbourne, Melbourne, Vic, Australia
    Neurodegener Dis 10:161-5. 2012
    ..The noninvasive evaluation of nigrostriatal dopaminergic integrity by PET can provide useful information for the differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD)...
  16. ncbi request reprint In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease
    Victor L Villemagne
    Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health, Heidelber, Australia
    Arch Neurol 68:905-12. 2011
    ....
  17. doi request reprint Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    J Nucl Med 52:1210-7. 2011
    ....
  18. doi request reprint BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease
    Yen Ying Lim
    Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia
    Neurobiol Aging 34:2457-64. 2013
    ..High Aβ levels coupled with Met carriage may be useful prognostic markers of accelerated cognitive decline and hippocampal degeneration in individuals in the preclinical stage of AD. ..
  19. doi request reprint Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study
    Kerryn E Pike
    Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Vic, Australia
    Neuropsychologia 49:2384-90. 2011
    ..The finding of gender differences deserves further research to answer definitively the important question of gender susceptibility to adverse cognitive effects from β-amyloid...
  20. doi request reprint Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease
    Gael Chetelat
    Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
    Brain 134:798-807. 2011
    ....
  21. doi request reprint Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's disease
    Andrew D Watt
    Department of Pathology, The University of Melbourne, Parkville, Melbourne, Victoria, Australia
    J Alzheimers Dis 24:47-59. 2011
    ..Furthermore, the findings indicate that the incorporation of non-amyloid markers into predictive models, function to increase the accuracy of the diagnostic potential of Aβ...
  22. doi request reprint Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
    Eur J Nucl Med Mol Imaging 39:983-9. 2012
    ..The purpose of this analysis was to compare data on cortical Aβ deposition in subjects who had undergone both (11)C-PiB (PiB) and (18)F-florbetaben (FBB) PET imaging...
  23. doi request reprint Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's Disease Neuroimaging Initiative
    Kathryn A Ellis
    Department of Psychiatry, Academic Unit for Psychiatry of Old Age, University of Melbourne, Kew, Victoria, Australia
    Alzheimers Dement 6:291-6. 2010
    ..Cross-sectional analysis of baseline data is revealing links between cognition, brain amyloid burden, structural brain changes, biomarkers, and lifestyle...
  24. doi request reprint Characterization of PiB binding to white matter in Alzheimer disease and other dementias
    Michelle T Fodero-Tavoletti
    Department of Pathology, University of Melbourne, and Department of Nuclear Medicine, Centre for PET, Austin Hospital, Heidelberg, Victoria, Australia
    J Nucl Med 50:198-204. 2009
    ..Although the specificity of PiB for Abeta plaques in gray matter has been well described, the nature of PiB binding to white matter remains unclear. In this study, we characterized the binding of PiB to human white matter homogenates...
  25. pmc Incidence of cerebral microbleeds in preclinical Alzheimer disease
    Paul A Yates
    From the Department of Nuclear Medicine and Centre for PET P A Y, V L V, C C R, Austin Health, Heidelberg The University of Melbourne P A Y, P M D, C S, C C R, Parkville Department of Radiology P M D, P M P, C S, Royal Melbourne Hospital, Parkville National Ageing Research Institute D A, Parkville CSIRO Preventative Health Flagship O S, Parkville Florey Institute of Neuroscience and Mental Health K A E, C L M, V L V, The University of Melbourne, Parkville Academic Unit for Psychiatry of Old Age K A E, D A, Department of Psychiatry, The University of Melbourne, Kew, Victoria Centre of Excellence for Alzheimer s Disease Research and Care R N M, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Australia
    Neurology 82:1266-73. 2014
    ..We sought to determine the incidence and associations of lobar microbleeds (LMBs) in a longitudinal cohort with (11)C-Pittsburgh compound B (PiB) PET imaging...
  26. doi request reprint Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172
    Graeme J O'Keefe
    Centre for Positron Emission Tomography, Austin Hospital, Heidelberg, Victoria, Australia
    J Nucl Med 50:309-15. 2009
    ..The radiation dosimetry of Abeta radioligands may influence their application; therefore, we calculated and compared the effective doses (EDs) of 11C-PiB and a new 18F-labeled ligand, 18F-BAY94-9172...
  27. ncbi request reprint Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, VIC 3084, Australia
    Lancet Neurol 12:357-67. 2013
    ..We aimed to use longitudinal data to calculate the rates of amyloid β (Aβ) deposition, cerebral atrophy, and cognitive decline...
  28. ncbi request reprint Relationship between memory performance and β-amyloid deposition at different stages of Alzheimer's disease
    Gael Chetelat
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Vic, Australia
    Neurodegener Dis 10:141-4. 2012
    ..The development of Aβ ligands for in vivo PET imaging has greatly facilitated the assessment of this question...
  29. doi request reprint In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133
    Nobuyuki Okamura
    Department of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australia
    J Nucl Med 51:223-8. 2010
    ..PET provides a noninvasive means to evaluate the functional integrity of the presynaptic monoaminergic system in the living human brain...
  30. doi request reprint Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease
    Yen Ying Lim
    Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia
    Neuropsychology 27:322-32. 2013
    ..We aimed to determine the extent to which high Aβ amyloid influenced cognitive function in healthy older adults and adults with MCI...
  31. ncbi request reprint Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B
    Steven Y Ng
    Department of Nuclear Medicine and Centre for Positron Emission Tomography, Austin Health, Melbourne, Australia
    Arch Neurol 64:1140-4. 2007
    ..However, patients presenting with atypical or focal clinical symptoms such as language or visuospatial dysfunction often pose a diagnostic challenge...
  32. doi request reprint Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests
    Alex Bahar-Fuchs
    Department of Nuclear Medicine, Centre for PET, Austin Health, Melbourne, Vic, Australia
    J Alzheimers Dis 33:451-62. 2013
    ..In conclusion, a measure of story recall may increase the confidence in making a diagnosis of MCI due to AD in clinical settings...
  33. doi request reprint Subacute ischemic stroke is associated with focal 11C PiB positron emission tomography retention but not with global neocortical Aβ deposition
    John V Ly
    University of Melbourne, Carlton South, Australia
    Stroke 43:1341-6. 2012
    ..Specifically, we hypothesized that patients with recent ischemic stroke have higher local and neocortical PiB positron emission tomography retention and that this may be associated with major vascular risk factors...
  34. doi request reprint The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies
    Seok Ming Lim
    Department of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australia
    J Nucl Med 50:1638-45. 2009
    ....
  35. ncbi request reprint Advances in structural and molecular neuroimaging in Alzheimer's disease
    Kathryn A Ellis
    Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Melbourne, Vic, Australia
    Med J Aust 194:S20-3. 2011
    ....
  36. pmc Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study
    Yen Ying Lim
    Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
    PLoS ONE 9:e86498. 2014
    ..We aimed to determine whether BDNF Val66Met polymorphism influences changes in memory performance, hippocampal volume, and Aβ accumulation in adults with amnestic mild cognitive impairment (aMCI) and high Aβ...
  37. doi request reprint Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS)
    Yen Ying Lim
    Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia
    Arch Clin Neuropsychol 28:320-30. 2013
    ..This may potentially be used to inform future estimates of cognitive change in clinical trials...
  38. doi request reprint Larger temporal volume in elderly with high versus low beta-amyloid deposition
    Gael Chetelat
    Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
    Brain 133:3349-58. 2010
    ..Our complementary analyses tend to support the latter hypotheses. Overall, our findings suggest that the deleterious effects of β-amyloid on cognition may be delayed in those subjects with larger brain (temporal) volume...
  39. ncbi request reprint Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL)
    Kathryn A Ellis
    Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne St Vincent s Aged Psychiatry Service, St George s Hospital, Kew, Victoria, Australia
    Int Psychogeriatr 26:543-54. 2014
    ..The first aim was to compute rates of transition from HC to MCI, and MCI to AD. The second aim was to characterize the cognitive profiles of individuals who transitioned to a more severe disease stage compared with those who did not...
  40. ncbi request reprint Amyloid imaging in Alzheimer's disease and other dementias
    Michelle T Fodero-Tavoletti
    Department of Pathology, The University of Melbourne, Melbourne, Victoria, 3010, Australia
    Brain Imaging Behav 3:246-61. 2009
    ....
  41. doi request reprint High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types
    Victor L Villemagne
    Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Health, Heidelberg, Australia
    Arch Neurol 66:1537-44. 2009
    ..Mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) genes lead to increased Abeta levels before symptoms arise...
  42. doi request reprint 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease
    Michelle T Fodero-Tavoletti
    Department of Pathology, The University of Melbourne, Victoria, 3010, Australia
    Brain 134:1089-100. 2011
    ..The preclinical examination of THK523 has demonstrated its high affinity and selectivity for tau pathology both in vitro and in vivo, indicating that (18)F-THK523 fulfils ligand criteria for human imaging trials...
  43. ncbi request reprint Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study
    Robert H Pietrzak
    Robert H Pietrzak, PhD, MPH, J Cobb Scott, PhD, United States Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Clinical Neurosciences Division, VA Connecticut Healthcare System, West Haven and Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA Alexander Neumeister, MD, Departments of Psychiatry and Radiology, New York University School of Medicine, New York, USA Yen Ying Lim, PhD, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia David Ames, MD, Academic Unit for Psychiatry of Old Age, St Vincent s Health, Department of Psychiatry, The University of Melbourne, Kew and National Ageing Research Institute, Parkville, Victoria, Australia Kathryn A Ellis, PhD, The Florey Institute of Neuroscience and Mental Health, Parkville, Academic Unit for Psychiatry of Old Age, St Vincent s Health, Department of Psychiatry, The University of Melbourne, Kew and National Ageing Research Institute, Parkville, Victoria, Pest Infestation Laboratory
    Br J Psychiatry 204:400-1. 2014
    ..These findings suggest that interventions to mitigate anxiety symptoms may help delay memory decline in otherwise healthy older adults with elevated beta-amyloid. ..
  44. ncbi request reprint Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET
    Sascha Mitkovski
    Department of Nuclear Medicine and Centre for PET, Austin Hospital, Victoria 3084, Melbourne, Australia
    Nucl Med Biol 32:585-91. 2005
    ..We sought to evaluate a minimally invasive method for quantification of nAChR distribution in the normal human brain, suitable for routine clinical application, using 2[(18)F]F-A-85380 and positron emission tomography (PET)...
  45. ncbi request reprint Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease
    Steven Ng
    Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    J Nucl Med 48:547-52. 2007
    ..The aim of this study was to explore the clinical potential of Abeta imaging for the diagnosis of AD by comparison of the accuracy of visual reading of (11)C-PIB images with quantitative analysis and (18)F-FDG...
  46. ncbi request reprint Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease
    Vincent Dore
    CSIRO Preventative Health National Research Flagship ICTC, the Australian e Health Research Centre BioMedical, Royal Brisbane and Women s Hospital, Herston, Queensland, Australia
    JAMA Neurol 70:903-11. 2013
    ..We aimed to further characterize the cross-sectional and longitudinal relationship between Aβ deposition, gray matter atrophy, and cognitive impairment...
  47. doi request reprint Quantitative approaches to amyloid imaging
    Victor L Villemagne
    Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, VIC 3084, Australia
    Methods Mol Biol 680:201-25. 2011
    ..With the availability of novel amyloid imaging agents radiolabeled with either (11)C (half-life 20 min) or (18)F (half-life 110 min), a description of different image acquisition approaches is provided...
  48. ncbi request reprint Personal memory function in mild cognitive impairment and subjective memory complaints: results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing
    Rachel F Buckley
    Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Vic, Australia The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Vic, Australia
    J Alzheimers Dis 40:551-61. 2014
    ..Mild cognitive impairment (MCI) is routinely diagnosed with the aid of neuropsychological tests, which do not tap the ABM and PSM domains...
  49. pmc Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: the AIBL Active trial
    Elizabeth V Cyarto
    National Ageing Research Institute, Melbourne, Australia
    BMC Psychiatry 12:167. 2012
    ..The aim of AIBL Active is to determine whether a 24-month physical activity program can delay the progression of white matter changes on magnetic resonance imaging (MRI)...
  50. doi request reprint 11C-PiB PET ABri imaging in Worster-Drought syndrome (familial British dementia): a case report
    Victor L Villemagne
    Mental Health Research Institute, University of Melbourne, Melbourne, Vic, Australia
    J Alzheimers Dis 19:423-8. 2010
    ..We speculate that the sparsity of ABri plaques in the neocortex together with its high deposition in the cerebellum, might explain the observed pattern of 11C-PiB retention...
  51. doi request reprint Amyloid-β: the seeds of darkness
    Michelle T Fodero-Tavoletti
    Department of Pathology, Bio21 Molecular and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia
    Int J Biochem Cell Biol 43:1247-51. 2011
    ..Although Alzheimer's disease remains incurable, improvements to Aβ immunotherapies and strategies to target Aβ continue to evolve, with the reliance upon Aβ imaging to shed light on the outcome of therapeutics proving very useful...
  52. doi request reprint Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease
    Victor L Villemagne
    Mental Health Research Institute, The University of Melbourne, Parkville, Melbourne, Victoria 3052, Australia
    J Neurosci 30:6315-22. 2010
    ..These results indicate that fundamental biochemical events relevant to AD can be monitored in blood, and that the species detected may be useful clinical biomarkers for AD...
  53. ncbi request reprint In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease
    Victor L Villemagne
    Centre for PET, Austin Health, Melbourne, Australia
    Eur J Nucl Med Mol Imaging 41:816-26. 2014
    ..A non-invasive method of determining brain tau burden in vivo would allow a better understanding of the pathophysiology of tauopathies. The purpose of the study was to evaluate (18)F-THK523 as a potential tau imaging tracer...
  54. ncbi request reprint Long night's journey into the day: amyloid-β imaging in Alzheimer's disease
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Vic, Australia
    J Alzheimers Dis 33:S349-59. 2013
    ....
  55. doi request reprint Amyloid imaging
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australia
    Int Psychogeriatr 23:S41-9. 2011
    ..Further longitudinal observations, coupled with different disease-specific tracers and biomarkers, are required to confirm this hypothesis and further elucidate the precise role of Aβ deposition in the course of AD...
  56. doi request reprint Cerebral β-amyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator-related hemorrhage
    John V Ly
    National Stroke Research Institute, Austin Health, University of Melbourne, Heidelberg Heights, Australia
    Ann Neurol 68:959-62. 2010
    ..This finding may provide an impetus for the development of a more practical rapid pretreatment screening technique...
  57. ncbi request reprint Assessment of the role of FDG PET in the diagnosis and management of children with refractory epilepsy
    Glenn P Ollenberger
    Department of Nuclear Medicine and Centre for PET, University of Melbourne, Melbourne, Australia
    Eur J Nucl Med Mol Imaging 32:1311-6. 2005
    ..We performed a retrospective analysis of the results of FDG PET scans in children with refractory epilepsy referred to our centre over an 8-year period, with a view to ascertaining the impact of FDG PET on subsequent patient management...
  58. ncbi request reprint In vitro characterization of Pittsburgh compound-B binding to Lewy bodies
    Michelle T Fodero-Tavoletti
    Department of Pathology, The University of Melbourne, Melbourne, Victoria 3010, Australia
    J Neurosci 27:10365-71. 2007
    ..These studies indicate that PIB retention observed within the cortical gray matter regions of DLB subjects in [11C]-PIB PET studies is largely attributable to PIB binding to Abeta plaques and not Lewy bodies...
  59. ncbi request reprint The Women's Healthy Ageing Project: fertile ground for investigation of healthy participants 'at risk' for dementia
    Cassandra E I Szoeke
    Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
    Int Rev Psychiatry 25:726-37. 2013
    ....
  60. ncbi request reprint Quantitative gait analysis in patients with dementia with Lewy bodies and Alzheimer's disease
    John R Merory
    Medical and Cognitive Research Unit, Neurology Department, Austin Health, Melbourne, Australia
    Gait Posture 26:414-9. 2007
    ..Significant correlations were found between gait speeds and gait outcome variables. Spatiotemporal gait characteristics of people with AD and DLB are similar, but significantly different from the normal population...
  61. ncbi request reprint Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease
    V L Villemagne
    Department of Nuclear Medicine, Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
    Neuropsychologia 46:1688-97. 2008
    ..These observations suggest that neither memory decline nor Abeta deposition are part of normal ageing and likely represent preclinical AD. Further longitudinal observations are required to confirm this hypothesis...
  62. ncbi request reprint Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease
    Victor L Villemagne
    Department of Nuclear Medicine, Centre for PET, Austin Hospital, Melbourne, Vic, Australia
    J Clin Neurosci 12:221-30. 2005
    ..From this, the prospect of specific preclinical diagnosis arises, possibly in conjunction with other related A beta biomarkers in plasma and CSF...
  63. ncbi request reprint Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer
    Kelvin K Yap
    Centre for PET, University of Melbourne, Austin Hospital Heidelberg, Victoria, 3084, Australia
    Eur J Nucl Med Mol Imaging 32:1033-40. 2005
    ....
  64. doi request reprint The relationship between nicotinic receptors and cognitive functioning in healthy aging: An in vivo positron emission tomography (PET) study with 2-[(18)F]fluoro-A-85380
    J R Ellis
    Monash University, Victoria, Australia
    Synapse 63:752-63. 2009
    ..However, this approach may be appropriate for use in pathologies considered to undergo extensive nAChR loss such as Alzheimer's disease and Parkinson's disease...
  65. doi request reprint 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease
    V L Villemagne
    Department of Nuclear Medicine, Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
    J Neurol Neurosurg Psychiatry 80:998-1001. 2009
    ..The purpose of this study was to explore the premortem diagnostic utility of (11)C-PiB PET in sporadic Creutzfeldt-Jakob disease (CJD)...
  66. ncbi request reprint Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study
    J R Ellis
    Department of Nuclear Medicine and Centre for PET, Austin Hospital, 145 Studley Road, Heidelberg, Victoria 3084, Australia
    Neurobiol Learn Mem 90:404-12. 2008
    ..It is possible that while the clinical 2-FA PET method described here may be insensitive in detecting changes in early AD, such changes may be detected in more advanced stages of the illness...
  67. doi request reprint Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET
    J R Ellis
    School of Psychology, Psychiatry, and Psychological Medicine, Monash University, Melbourne, Victoria, Australia
    Psychopharmacology (Berl) 202:79-91. 2009
    ..e., galantamine) that potentiate cholinergic neurotransmission improve cognitive function in Alzheimer's disease (AD); however, the relationship between these effects and associated changes in nAChRs are yet to be established in vivo...
  68. ncbi request reprint Rare genetically defined causes of dementia
    K E Novakovic
    Department of Nuclear Medicine, Centre for PET Austin Hospital, Melbourne, Victoria, Australia
    Int Psychogeriatr 17:S149-94. 2005
    ..Awareness of these disorders, allied with recent advances in genetic, biochemical and neuroimaging techniques, may lead to early diagnosis, successful treatment and better prognosis...
  69. doi request reprint 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage
    J V Ly
    National Stroke Research Institute, Level 1, Neurosciences Building, Austin Health, University of Melbourne, 300 Waterdale Rd, Heidelberg Heights, Victoria 3081, Australia
    Neurology 74:487-93. 2010
    ..We hypothesized that patients with a clinical diagnosis of CAA-related hemorrhage (CAAH) have increased (11)C-PIB uptake and that the pattern differs from Alzheimer disease (AD)...